Inherited pediatric metabolic epilepsies

Bibliography

• Thony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydroalse I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase genes. Human Mutat 2006;27:870-8
   PubMed Web of Science ®Google Scholar
• Opladen T, Hoffmann FG, Blau N. Neurotransmitter disorders: a survey of patients with treatable tetrahydrobiopterin deficiencies. Ann Neurol 2012; Submitted
   Google Scholar
• Blau N, Burgard P. Disorders of phenylalanine and tetrahydrobiopterin. In: Blau N, Hoffmann FG, Leonard J, Clarke J, editors. Physician's guide to the treatment and follow-up of metabolic diseases. Springer; Heidelberg: 2006. p. 25-34
   Google Scholar
• Walter JH, Lachmann RH, Burgard P. Hyperphenylalaninaemia. In: Saudubray JM, van den Berghe G, Walter JH, editors. Inborn metabolic diseases: diagnosis and treatment. 5th editoin. Springer; New York, NY: 2012. p. 262-3
   Google Scholar
• Blau N, Thony B, Cotton RGH, Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic & molecular bases of inherited disease. McGraw-Hill; New York: 2001. p. 1725-76
   Google Scholar
• Ponzone A, Ferraris S, Baglieri S, Treatment of tetrahydrobiopterin deficiencies. In: Blau N, editor. PKU and BH4: advances in phenylketonuria and tetrahydrobiopterin. SPS Verlagsgesellschaft; Heilbronn: 2006. p. 612-37
   Google Scholar
• Raemakers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol 2004;46:843-51
   Google Scholar
• Blau N, Bonafe L, Krageloh-Mann I, Cerebrospinal fluid pterins and folates in Aicardi-Goutieres syndrome: a new phenotype. Neurology 2003;61(5):642-7
   Google Scholar
• Jones AG, Hattersley AT. Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nat Rev Endocrinol 2010;6(6):347-51
   Google Scholar
• Ramaekers VT, Hausler M, Opladen T, Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 2002;33(6):301-8
   Google Scholar
• Schubiger G, Caflisch U, Baumgartner R, Biotinidase deficiency: clinical course and biochemical findings. J Inherit Metab Dis 1984;7(3):129-30
   Google Scholar
• Tabatabaie L, Klomp LW, Berger R, de Koning TJ. L-serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 2010;99:256-62
   PubMed Web of Science ®Google Scholar
• de Koning TJ, Klomp LW, Van Oppen AC, Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 2004;364(9452):2221-2
   PubMed Web of Science ®Google Scholar
• De Koning TJ, Jaeken J, Pineda M, Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 2000;31:297-2
   Google Scholar
• Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000;80(3):1107-213
   PubMed Web of Science ®Google Scholar
• Stockler S, Holzbach U, Hanefeld F, Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 1994;36(3):409-13
   PubMed Web of Science ®Google Scholar
• Anselm IA, Coulter DL, Darras BT. Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8. Neurology 2008;70(18):1642-4
   Google Scholar
• Mercimek-Mahmutoglu S, Connolly MB, Poskitt K, Treatment of intractable epilepsy in a female with SLC6A8 deficiency. Mol Genet Metab 2010;101:409-12
   Google Scholar
• Kamp v d JM, Mancini GM, Pouwels PJ, Clinical features and X-inactivation in females heterozygous for creatine transporter defect. Clin Genet 2011;79:264-72
   Google Scholar
• Schulze A, Battini R. Pre-symptomatic treatment of creatine biosynthesis defects. Subcell Biochem 2007;46:167-81
   Google Scholar
• Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996;348(9030):789-90
   PubMed Web of Science ®Google Scholar
• Fons C, Sempere A, Sanmarti FX, Epilepsy spectrum in cerebral creatine transporter deficiency. Epilepsia 2009;50(9):2168-9
   Google Scholar
• Valayannopoulos V, Boddaert N, Chabli A, Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect. J Inherit Metab Dis 2012;35(1):151-7
   PubMed Web of Science ®Google Scholar
• Braissant O, Bachmann C, Henry H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell Biochem 2007;46:67-81
   Google Scholar
• Shimomura K, Horster F, de Wet H, A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007;69(13):1342-9
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Pearson ER, Antcliff JF, Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350(18):1838-49
   PubMed Web of Science ®Google Scholar
• Babenko AP, Polak M, Cave H, Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355(5):456-66
   PubMed Web of Science ®Google Scholar
• Proks P, Arnold AL, Bruining J, A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006;15(11):1793-800
   PubMed Web of Science ®Google Scholar
• Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54(9):2503-13
   PubMed Web of Science ®Google Scholar
• Ashcroft FM. ATP-sensitive K-channels and disease: from molecule to malady. Am J Physiol 2007;293:E880-9
   PubMed Web of Science ®Google Scholar
• Slingerland AS, Nuboer R, Hadders-Algra M, Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006;49(11):2559-63
   PubMed Web of Science ®Google Scholar
• Pearson ER, Flechtner I, Njølstad PR, Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355(5):467-77
   PubMed Web of Science ®Google Scholar
• Ashcroft FM. New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab 2010;11(3):179-81
   PubMed Web of Science ®Google Scholar
• Shimomura K, Girard CA, Proks P, Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. Diabetes 2006;55(6):1705-12
   Google Scholar
• Mannikko R, Jefferies C, Flanagan SE, Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms. Hum Mol Genet 2010;19(6):963-72
   Google Scholar
• Zwaveling-Soonawala N, Hagebeuk EE, Slingerland AS, Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation. Diabetologia 2011;54(2):469-71
   Web of Science ®Google Scholar
• Gurgel LC, Crispim F, Noffs MHS, Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function. Diabetes Care 2007;30(11):108
   Google Scholar
• Koster JC, Kurata HT, Enkvetchakul D, DEND mutation in Kir6.2 (KCNJ11) reveals a flexible N-terminal region critical for ATP-sensing of the KATP channel. Biophys J 2008;95(10):4689-97
   Google Scholar
• Slingerland AS, Nuboer R, Hadders-Algra M, Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006;49(11):2559-63
   PubMed Web of Science ®Google Scholar
• Mlynarski W, Tarasov AI, Gach A, Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 2007;3(11):640-5
   Google Scholar
• Hudson RC, Daniel RM. L-glutamate dehydrogenases: distribution, properties and mechanism. Comp Biochem Physiol B 1993;106(4):767-92
   Google Scholar
• Bryla J, Michalik M, Nelson J, Regulation of the glutamate dehydrogenase activity in rat islets of langerhans and its consequence on insulin release. Metabolism 1994;43:1187-95
   PubMed Web of Science ®Google Scholar
• Sperling MA, Menon RK. Hyperinsulinemic hypoglycemia of infancy. Endocrin Metab Clin N Am 1999;28:695-708
   Google Scholar
• Raizen DM, Brooks-Kayal A, Steinkrauss L, Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations. J Pediatr 2005;146(3):388-94
   Google Scholar
• Bahi-Buisson N, Roze E, Dionisi C, Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. Dev Med Child Neurol 2008;50(12):945-9
   PubMedGoogle Scholar
• Bahi-Buisson N, El Sabbagh S, Soufflet C, Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase. Seizure 2008;17(7):658-64
   Google Scholar
• Perez Errazquin F, Sempere Fernandez J, Garcia Martin G, Hyperinsulinism and hyperammonaemia syndrome and severe myoclonic epilepsy of infancy. Neurologia 2011;26(4):248-52
   Google Scholar
• Palladino AA, Stanley CA. The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord 2010;11(3):171-8
   Google Scholar
• Palladino AA, Stanley CA. The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord 2010;11(3):171-8
   Google Scholar
• Hussain K, Aynsley-Green A, Stanley CA. Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). Pediatr Endocrinol Rev 2004;2(Suppl 1):163-7
   Google Scholar
• Smith TJ, Stanley CA. Untangling the glutamate dehydrogenase allosteric nightmare. Trends Biochem Sci 2008;33:557-64
   PubMed Web of Science ®Google Scholar
• Wang D, Kranz-Eble P, De Vivo DC. Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome. Hum Mutat 2000;16(3):224-31
   Google Scholar
• Klepper J, Scheffer H, Elsaid MF, Autosomal recessive inheritance of GLUT1 deficiency syndrome. Neuropediatrics 2009;40(5):207-10
   Google Scholar
• Rotstein M, Engelstad K, Yang H, Glut1 deficiency: inheritance pattern determined by haploinsufficiency. Ann Neurol 2010;68(6):955-8
   Google Scholar
• De Vivo DC, Trifiletti RR, Jacobson RI, Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325(10):703-9
   PubMed Web of Science ®Google Scholar
• Santer R, Klepper J. Disorders of glucose transport. In: Saudubray JM, van den Berghe G, Walter JH, editors. Inborn metabolic diseases: diagnosis and treatment. 5th edition. Springer; New York, NY: 2012. p. 179
   Google Scholar
• Hunt AD, Stokes J, McCrory WW, Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 1954;13(2):140-5
   Google Scholar
• Mills PB, Struys E, Jakobs C, Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006;12:307-9
   PubMed Web of Science ®Google Scholar
• Gallagher RC, Van Hove JL, Scharer G, Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009;65(5):550-6
   Google Scholar
• Basura GJ, Hagland SP, Wiltse AM, Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009;168:697-704
   PubMed Web of Science ®Google Scholar
• Kanno J, Kure S, Narisawa A, Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab 2007;91:384-9
   Google Scholar
• Plecko B, Paul K, Paschke E, Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007;28:19-26
   PubMed Web of Science ®Google Scholar
• Pearl PL, Gospe SM. Pyridoxal phosphate dependency, a newly recognized treatable catastrophic epileptic encephalopathy. J Inherit Metab Dis 2007;30(1):2-4
   Google Scholar
• Mills PB, Surtees RA, Champion MP, Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase. Human Mol Genet 2005;14(8):1077-86
   Google Scholar
• Hoffmann FG, Schmitt B, Windfuhr M, Pyridoxal 5’-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007;30:96-9
   PubMed Web of Science ®Google Scholar
• Stockler S, Plecko B, Gospe SM, Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011;104(1-2):48-60
   PubMed Web of Science ®Google Scholar
• Plecko B, Hikel C, Korenke G-C, Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy. Neuropediatrics 2005;36:200-5
   Google Scholar
• Mills PB, Footitt EJ, Ceyhan S, Urinary AASA excretion is elevated in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. J Inherit Metab Dis 2012;35(6):1031-6
   Google Scholar
• Mills PB, Footitt EJ, Mills KA, Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010;133:2148-59
   PubMed Web of Science ®Google Scholar
• Baxter P. Pyridoxine dependent and pyridoxine responsive seizures. In: Baxter P, editor. Vitamin responsive conditions in paediatric neurology. International review of child neurology series MacKeith Press; London: 2001. p. 109-65
   Google Scholar
• Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002;26:181-5
   Google Scholar
• Baxter P, Griffiths P, Kelly T, Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996;38:998-1006
   PubMed Web of Science ®Google Scholar
• Baynes K, Tomaszewski Farias S, Gospe SM. Pyridoxine-dependent seizures and cognition in adulthood. Dev Med Child Neurol 2003;45:782-5
   PubMed Web of Science ®Google Scholar
• Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998;102(6):E69
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Danney M, Waber LJ, Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1630-4
   PubMed Web of Science ®Google Scholar
• Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001;138(1 Suppl):S30-9
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Nassogne MC. Disorders of the urea cycle and related enzymes. In: Saudubray JM, van den Berghe G, Walter JH, editors. Inborn metabolic diseases: diagnosis and treatment. 5th edition. Springer; New York, NY: 2012. p. 304-8
   Google Scholar
• Summar ML, Dobbelaere D, Brusilow S, Symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008;97(10):1420-5
   Google Scholar
• Summar ML, Barr F, Dawling S, Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin 2005;21(4 Suppl):S1-8
   Web of Science ®Google Scholar
• Dealberto MJ, Sarazin FF. Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: a case report in the psychiatric setting. J Neuropsychiatry Clin Neurosci 2008;20(3):369-71
   Web of Science ®Google Scholar
• Thakur V, Rupar CA, Ramsay DA, Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. Pediatr Crit Care Med 2006;7(3):273-6
   Google Scholar
• Mineyko A, Whiting S, Graham GE. Hyperekplexia: treatment of a severe phenotype and review of the literature. Can J Neurol Sci 2011;38:411-16
   PubMed Web of Science ®Google Scholar
• Tijssen MA, Schoemaker HC, Edelbroek PJ, The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci 1997;149(1):63-7
   Google Scholar
• Vigevano F, Di Capua M, Dalla Bernardina B. Startle disease: an avoidable cause of sudden infant death. Lancet 1989;1:216
   Google Scholar
• Masia R, Koster JC, Tumini S, An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes 2007;56(2):328-36
   PubMed Web of Science ®Google Scholar